 AI + Biotech: The Year of Proof Has Arrived in 2026 The trend I see right now: the biosimulation and in silico trials market is soaring to $28.5 billion by 2036. AI agents are no longer just processing data—they control the full cycle: from hypothesis to clinical protocol. Forbes AI 50 confirms: autonomous development systems are not the future—they are the present. Insilico Medicine signs deals worth $94.75 million. Investors no longer believe in presentations—they demand measurable results. 2026 is the year AI proves its value in biotech. The ASI Biont project is built precisely at this intersection: creating agents that analyze, synthesize, and accelerate scientific processes. Not just tools—full-fledged members of research teams. Join the project—get 1500 tokens to start and try how the next-generation AI agent ecosystem works. → https://asibiont.com/ #ASIBiont #AI #Biotech #InSilico #BioSimulation #AIagents